These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 37102608)

  • 1. Inactivation of p53 provides a competitive advantage to del(5q) myelodysplastic syndrome hematopoietic stem cells during inflammation.
    Muto T; Walker CS; Agarwal P; Vick E; Sampson A; Choi K; Niederkorn M; Ishikawa C; Hueneman K; Varney M; Starczynowski DT
    Haematologica; 2023 Oct; 108(10):2715-2729. PubMed ID: 37102608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Higher-risk myelodysplastic syndromes with del(5q): does the del(5q) matter?
    Gorshein E; Weber UM; Gore S
    Expert Rev Hematol; 2020 Mar; 13(3):233-239. PubMed ID: 32067540
    [No Abstract]   [Full Text] [Related]  

  • 3. Deletion 5q MDS: molecular and therapeutic implications.
    Komrokji RS; Padron E; Ebert BL; List AF
    Best Pract Res Clin Haematol; 2013 Dec; 26(4):365-75. PubMed ID: 24507813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The 5q deletion size in myeloid malignancies is correlated to additional chromosomal aberrations and to TP53 mutations.
    Stengel A; Kern W; Haferlach T; Meggendorfer M; Haferlach C
    Genes Chromosomes Cancer; 2016 Oct; 55(10):777-85. PubMed ID: 27218649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion.
    Sebaa A; Ades L; Baran-Marzack F; Mozziconacci MJ; Penther D; Dobbelstein S; Stamatoullas A; Récher C; Prebet T; Moulessehoul S; Fenaux P; Eclache V
    Genes Chromosomes Cancer; 2012 Dec; 51(12):1086-92. PubMed ID: 22933333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of Tifab, a del(5q) MDS gene, alters hematopoiesis through derepression of Toll-like receptor-TRAF6 signaling.
    Varney ME; Niederkorn M; Konno H; Matsumura T; Gohda J; Yoshida N; Akiyama T; Christie S; Fang J; Miller D; Jerez A; Karsan A; Maciejewski JP; Meetei RA; Inoue J; Starczynowski DT
    J Exp Med; 2015 Oct; 212(11):1967-85. PubMed ID: 26458771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic Outcomes and Prognostic Impact of Gene Mutations Including TP53 and SF3B1 in Patients with Del(5q) Myelodysplastic Syndromes (MDS).
    Chan O; Ali NA; Sallman D; Padron E; Lancet J; Komrokji R
    Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):e467-e476. PubMed ID: 35101379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-cell transcriptional profile of CD34+ hematopoietic progenitor cells from del(5q) myelodysplastic syndromes and impact of lenalidomide.
    Serrano G; Berastegui N; Díaz-Mazkiaran A; García-Olloqui P; Rodriguez-Res C; Huerga-Dominguez S; Ainciburu M; Vilas-Zornoza A; Martin-Uriz PS; Aguirre-Ruiz P; Ullate-Agote A; Ariceta B; Lamo-Espinosa JM; Acha P; Calvete O; Jimenez T; Molero A; Montoro MJ; Díez-Campelo M; Valcarcel D; Solé F; Alfonso-Pierola A; Ochoa I; Prósper F; Ezponda T; Hernaez M
    Nat Commun; 2024 Jun; 15(1):5272. PubMed ID: 38902243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Knockdown of HSPA9 induces TP53-dependent apoptosis in human hematopoietic progenitor cells.
    Liu T; Krysiak K; Shirai CL; Kim S; Shao J; Ndonwi M; Walter MJ
    PLoS One; 2017; 12(2):e0170470. PubMed ID: 28178280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CSNK1A1 mutations and isolated del(5q) abnormality in myelodysplastic syndrome: a retrospective mutational analysis.
    Smith AE; Kulasekararaj AG; Jiang J; Mian S; Mohamedali A; Gaken J; Ireland R; Czepulkowski B; Best S; Mufti GJ
    Lancet Haematol; 2015 May; 2(5):e212-21. PubMed ID: 26688096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic Copy Number Variations in the Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients with del(5q) and/or -7/del(7q).
    Zhang R; Kim YM; Wang X; Li Y; Lu X; Sternenberger AR; Li S; Lee JY
    Int J Med Sci; 2015; 12(9):719-26. PubMed ID: 26392809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular pathogenesis of myelodysplastic syndromes with deletion 5q.
    Lee JH; List A; Sallman DA
    Eur J Haematol; 2019 Mar; 102(3):203-209. PubMed ID: 30578738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients.
    Caceres G; McGraw K; Yip BH; Pellagatti A; Johnson J; Zhang L; Liu K; Zhang LM; Fulp WJ; Lee JH; Al Ali NH; Basiorka A; Smith LJ; Daugherty FJ; Littleton N; Wells RA; Sokol L; Wei S; Komrokji RS; Boultwood J; List AF
    Proc Natl Acad Sci U S A; 2013 Oct; 110(40):16127-32. PubMed ID: 24043769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myeloid malignancies with chromosome 5q deletions acquire a dependency on an intrachromosomal NF-κB gene network.
    Fang J; Barker B; Bolanos L; Liu X; Jerez A; Makishima H; Christie S; Chen X; Rao DS; Grimes HL; Komurov K; Weirauch MT; Cancelas JA; Maciejewski JP; Starczynowski DT
    Cell Rep; 2014 Sep; 8(5):1328-38. PubMed ID: 25199827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes.
    Giagounidis A; Mufti GJ; Fenaux P; Germing U; List A; MacBeth KJ
    Ann Hematol; 2014 Jan; 93(1):1-11. PubMed ID: 24018623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation.
    Liu TX; Becker MW; Jelinek J; Wu WS; Deng M; Mikhalkevich N; Hsu K; Bloomfield CD; Stone RM; DeAngelo DJ; Galinsky IA; Issa JP; Clarke MF; Look AT
    Nat Med; 2007 Jan; 13(1):78-83. PubMed ID: 17159988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond.
    Talati C; Sallman D; List A
    Semin Hematol; 2017 Jul; 54(3):159-166. PubMed ID: 28958290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myelodysplastic syndromes del(5q): Pathogenesis and its therapeutic implications.
    Bruzzese A; Martino EA; Mendicino F; Lucia E; Olivito V; Capodanno I; Neri A; Morabito F; Vigna E; Gentile M
    Eur J Haematol; 2024 Jun; 112(6):860-869. PubMed ID: 38294126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide.
    Gaballa MR; Besa EC
    Ann Hematol; 2014 May; 93(5):723-33. PubMed ID: 24627193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new recurrent translocation, t(5;11)(q35;p15.5), associated with del(5q) in childhood acute myeloid leukemia. The UK Cancer Cytogenetics Group (UKCCG).
    Jaju RJ; Haas OA; Neat M; Harbott J; Saha V; Boultwood J; Brown JM; Pirc-Danoewinata H; Krings BW; Müller U; Morris SW; Wainscoat JS; Kearney L
    Blood; 1999 Jul; 94(2):773-80. PubMed ID: 10397745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.